Solventum Seeks Offers for Health Information Systems Business in Potential Divestiture
Solventum is reportedly collecting offers for its Health Information Systems business, signaling a possible portfolio review without confirming a buyer or deal.
STERIS’s $2.1 Billion Xodus Medical Deal Tests Healthcare M&A Appetite
STERIS’s $2.1 billion Xodus Medical agreement puts financing, dilution and medical-device M&A appeti…
Bristol Myers Squibb Stock Jumps on Rare Double Phase 3 Success
BMY shares rose 5.7% to 6.5% after two positive Phase 3 readouts, putting pipeline value and analyst…
Lipocine’s TLANDO Approval Opens a New Canadian Test for $LPCN
Health Canada’s approval of TLANDO gives Lipocine a Canadian commercial pathway, with Verity Pharma …
Merck and Moderna’s Positive Phase 3 Cancer Vaccine Data Reshape the Oncology Trade
Merck’s Keytruda gains and Moderna’s 9% stock pop highlight two distinct oncology narratives: establ…
Pfizer’s TUKYSA FDA Approval Opens a New Frontline Breast Cancer Growth Opportunity
Pfizer’s frontline FDA approval for TUKYSA could broaden its oncology opportunity as investors asses…
Perrigo Takeover Chatter Puts PRGO Shares on M&A Watch
Reported takeover interest has put Perrigo and its PRGO shares in the spotlight, but no buyer, offer…
Moderna and Merck Cancer Vaccine Trial Success Puts MRNA and MRK in Focus
Phase 3 melanoma data from Moderna and Merck may strengthen the case for mRNA oncology and add strat…
Teva Hits 52-Week High as FDA Clears First Once-Monthly Schizophrenia Injection
Teva’s WELTRUZA approval gives investors a potential specialty-medicine catalyst as the company adva…
XORTX Therapeutics Shares Jump 16.7% as Gout Program Moves Toward IND Filing
XORTX Therapeutics shares traded up 16.7% after news that its gout program is advancing toward an IN…